Apellis Pharmaceuticals, Inc. - Common Stock (APLS) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2017 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
APLS on Nasdaq
Shares outstanding
127,672,444
Price per share
$25.12
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
122,355,774
Total reported value
$2,771,670,915
% of total 13F portfolios
0%
Share change
-8,067,290
Value change
-$154,804,544
Number of holders
270
Price from insider filings
$25.12
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Apellis Pharmaceuticals, Inc. - Common Stock (APLS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
WELLINGTON MANAGEMENT GROUP LLP 11% +53% $311,174,879 +$107,289,396 13,750,547 +53% Wellington Management Group LLP 31 Oct 2025
MORGAN STANLEY 7.7% $172,285,808 9,592,751 Morgan Stanley 31 Dec 2024
Deep Track Capital, LP 5.6% $125,720,000 7,000,000 Deep Track Capital, LP 09 May 2025
BlackRock, Inc. 4.5% $100,550,353 5,598,572 BlackRock, Inc. 31 Mar 2025
EcoR1 Capital, LLC 2.7% $78,009,140 3,447,156 EcoR1 Capital, LLC 30 Sep 2025

As of 30 Sep 2025, 270 institutional investors reported holding 122,355,774 shares of Apellis Pharmaceuticals, Inc. - Common Stock (APLS). This represents 96% of the company’s total 127,672,444 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Apellis Pharmaceuticals, Inc. - Common Stock (APLS) together control 78% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Avoro Capital Advisors LLC 9.6% 12,222,222 0% 3.6% $276,588,884
VANGUARD GROUP INC 7.8% 9,987,394 -1.6% 0% $226,014,726
MORGAN STANLEY 7.6% 9,643,247 -1.1% 0.01% $218,226,680
WELLINGTON MANAGEMENT GROUP LLP 7.3% 9,290,960 +3.5% 0.04% $210,254,425
Deep Track Capital, LP 6.3% 8,000,382 +14% 5.1% $181,048,645
BlackRock, Inc. 4.9% 6,268,465 -2.1% 0% $141,855,364
AQR CAPITAL MANAGEMENT LLC 3.5% 4,487,354 -25% 0.07% $101,548,820
JENNISON ASSOCIATES LLC 3.4% 4,348,055 +63% 0.06% $98,396,482
STATE STREET CORP 3.2% 4,037,644 +13% 0% $91,371,884
EcoR1 Capital, LLC 2.7% 3,447,156 -71% 3.7% $78,009,140
UBS Group AG 2.7% 3,429,905 -28% 0.02% $77,618,750
SUVRETTA CAPITAL MANAGEMENT, LLC 2.3% 2,878,000 0% 2% $65,129,140
Polar Capital Holdings Plc 2.1% 2,650,230 +96% 0.29% $59,974,705
Siren, L.L.C. 2% 2,578,396 0% 2.3% $58,349,101
ORBIMED ADVISORS LLC 1.8% 2,323,368 +57% 1.3% $52,577,818
GEODE CAPITAL MANAGEMENT, LLC 1.6% 2,072,913 +3.9% 0% $46,919,472
DEUTSCHE BANK AG\ 1.2% 1,504,457 +0.55% 0.01% $34,045,862
Amundi 1.2% 1,493,678 -6.9% 0.01% $36,385,996
BANK OF AMERICA CORP /DE/ 1.2% 1,477,525 -39% 0% $33,436,382
BANK OF NOVA SCOTIA 1.1% 1,456,225 +145% 0.06% $32,954,369
MILLENNIUM MANAGEMENT LLC 1.1% 1,343,726 +564% 0.02% $30,408,519
ING GROEP NV 0.92% 1,174,500 +281% 0.14% $26,578,935
VOLORIDGE INVESTMENT MANAGEMENT, LLC 0.78% 992,269 +112% 0.08% $22,455,047
BNP PARIBAS FINANCIAL MARKETS 0.76% 972,474 0% 0.02% $22,007,087
Octagon Capital Advisors LP 0.71% 903,500 0% 3.2% $20,446,205

Institutional Holders of Apellis Pharmaceuticals, Inc. - Common Stock (APLS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 697,624 $17,501,579 +$882,088 $25.12 16
2025 Q3 122,355,774 $2,771,670,915 -$154,804,544 $22.63 270
2025 Q2 131,608,288 $2,279,077,423 +$66,148,357 $17.31 246
2025 Q1 126,465,800 $2,767,959,579 -$78,248,319 $21.87 252
2024 Q4 126,723,891 $4,044,170,293 +$224,206,429 $31.91 259
2024 Q3 118,165,642 $3,408,098,233 -$32,772,311 $28.84 261
2024 Q2 115,428,997 $4,426,484,074 -$4,063,210 $38.36 259
2024 Q1 113,103,917 $6,646,510,438 -$27,789,991 $58.78 296
2023 Q4 113,568,311 $6,800,298,011 +$75,955,536 $59.86 278
2023 Q3 113,630,426 $4,326,001,749 -$249,890,323 $38.04 250
2023 Q2 106,464,737 $9,698,740,546 -$322,780,479 $91.10 311
2023 Q1 110,363,167 $7,278,027,538 +$671,099,429 $65.96 277
2022 Q4 100,652,525 $5,202,853,976 +$66,260,972 $51.71 239
2022 Q3 97,643,165 $6,665,378,163 +$32,228,664 $68.30 245
2022 Q2 91,648,969 $4,144,516,571 +$31,626,482 $45.22 205
2022 Q1 90,940,512 $4,620,842,334 +$520,061,489 $50.81 206
2021 Q4 81,021,271 $3,829,991,538 +$612,446,955 $47.28 183
2021 Q3 69,511,931 $2,291,947,609 -$95,194,645 $32.96 174
2021 Q2 64,601,991 $4,083,171,314 +$13,404,010 $63.20 201
2021 Q1 63,358,839 $2,718,377,161 +$19,912,136 $42.91 168
2020 Q4 63,890,305 $3,654,164,157 -$7,921,158 $57.20 165
2020 Q3 62,139,394 $1,874,756,231 +$24,663,304 $30.17 143
2020 Q2 61,184,997 $1,997,919,282 +$197,934,910 $32.66 141
2020 Q1 55,273,539 $1,482,076,889 +$294,686,642 $26.79 143
2019 Q4 43,885,493 $1,343,772,430 +$85,692,286 $30.62 132
2019 Q3 40,388,376 $973,049,791 +$46,440,436 $24.09 129
2019 Q2 40,468,785 $1,025,057,247 +$17,474,333 $25.34 99
2019 Q1 40,125,707 $782,326,949 +$160,534,739 $19.50 92
2018 Q4 32,104,592 $423,490,077 -$27,345,727 $13.19 95
2018 Q3 29,708,993 $528,224,019 +$9,616,309 $17.78 79
2018 Q2 29,064,186 $639,413,620 +$265,705,567 $22.00 73
2018 Q1 17,039,592 $375,355,107 +$8,764,830 $22.11 46
2017 Q4 15,746,683 $340,174,825 +$340,174,825 $21.70 46